SGEM#293: CRASH in the US, CRASH in the US, CRASH-2 in the USA

Trials extracted from the podcast by Dr. Ken Milne

• 2020Mortality and Complication Rates in Adult Trauma Patients Receiving Tranexamic AcidEmergency & ResuscitationIn 273 adult trauma patients at a US Level I center, tranexamic acid was followed by 12.8% 28-day mortality and 6.6% thromboembolic events versus CRASH-2
• 2010CRASH-2Emergency & ResuscitationIn 20,211 adult trauma patients with or at risk of significant bleeding, tranexamic acid reduced all-cause mortality at 4 weeks compared with placebo.
• 2019CRASH-3Emergency & ResuscitationIn 12 737 adults with acute traumatic brain injury, tranexamic acid did not significantly reduce head injury-related death compared with placebo.
• 2019Mortality and Thrombosis in Injured Adults Receiving Tranexamic Acid in the Post-CRASH-2 EraEmergency & ResuscitationIn2536 injured adultsreceiving tranexamic acid,pooled thrombosis was 5.9% and 30-day mortality 10.1%versus 2.0% and 14.5% inCRASH-2